Literature DB >> 35354254

The use of hydroxyurea pretreatment in chronic myeloid leukemia in the current tyrosine kinase inhibitor era.

Camille C B Kockerols1, Inge Geelen2, Mark-David Levin3, Jeroen J W M Janssen4, Avinash G Dinmohamed5, Mels Hoogendoorn6, Jan J Cornelissen2, Peter E Westerweel3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35354254      PMCID： PMC9335097          DOI： 10.3324/haematol.2021.280501

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   11.047


× No keyword cloud information.
  6 in total

1.  Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  A Hochhaus; S Saussele; G Rosti; F-X Mahon; J J W M Janssen; H Hjorth-Hansen; J Richter; C Buske
Journal:  Ann Oncol       Date:  2018-10-01       Impact factor: 32.976

2.  Determination of the optimal chemotherapy drugs pretreatment time through cultivation of hemopoietic cells in CML-patients treated with tyrosine kinase inhibitors.

Authors:  I O Zhaleiko; T P Perekhrestenko; D I Bilko; I S Dyagil; N M Bilko
Journal:  Exp Oncol       Date:  2014-06

3.  Omitting cytogenetic assessment from routine treatment response monitoring in chronic myeloid leukemia is safe.

Authors:  Inge G P Geelen; Noortje Thielen; Jeroen J W M Janssen; Mels Hoogendoorn; Tanja J A Roosma; Peter J M Valk; Otto Visser; Jan J Cornelissen; Peter E Westerweel
Journal:  Eur J Haematol       Date:  2018-02-07       Impact factor: 2.997

4.  Longer Hydroxyurea Administration Prior to Imatinib Mesylate is Risk Factor for Unsuccessful Major Molecular Response in Chronic-Phase Chronic Myeloid Leukemia: Possibility of P-Glycoprotein Role.

Authors:  Ikhwan Rinaldi; Ary Harryanto Reksodiputro; Sri Widia Jusman; Alida Harahap; Rianto Setiabudy; Septelia Inawati Wanandi; Karmel Tambunan; Catharina Suharti
Journal:  Asian Pac J Cancer Prev       Date:  2019-12-01

5.  Treatment outcome in a population-based, 'real-world' cohort of patients with chronic myeloid leukemia.

Authors:  Inge G P Geelen; Noortje Thielen; Jeroen J W M Janssen; Mels Hoogendoorn; Tanja J A Roosma; Sten P Willemsen; Otto Visser; Jan J Cornelissen; Peter E Westerweel
Journal:  Haematologica       Date:  2017-08-31       Impact factor: 9.941

Review 6.  European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia.

Authors:  A Hochhaus; M Baccarani; R T Silver; C Schiffer; J F Apperley; F Cervantes; R E Clark; J E Cortes; M W Deininger; F Guilhot; H Hjorth-Hansen; T P Hughes; J J W M Janssen; H M Kantarjian; D W Kim; R A Larson; J H Lipton; F X Mahon; J Mayer; F Nicolini; D Niederwieser; F Pane; J P Radich; D Rea; J Richter; G Rosti; P Rousselot; G Saglio; S Saußele; S Soverini; J L Steegmann; A Turkina; A Zaritskey; R Hehlmann
Journal:  Leukemia       Date:  2020-03-03       Impact factor: 11.528
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.